Fundraising Fox

Sound Pharmaceuticals

Seattle, US · Delaware corporation

Sound Pharmaceuticals (SPI) is a Seattle-based biotech developing drug therapeutics, including its lead candidate SPI-1005, to prevent and treat sensorineural hearing loss, tinnitus, and Meniere's disease. Its treatments target inner ear disorders for which there are currently no FDA-approved drugs.

BiotechHealthtech

Founders & leadership

JK
Jonathan KilinFounder · CEO
JP
James Paul RickeyExecutive
EL
Eric LynchNamed on SEC filing

Board

GK
Glenn KawasakiBoard director
JA
Joseph AshleyBoard director

Reported raises · per SEC filings

Form D private placements

$12.5M disclosed across 2 rounds · 2015–2018

▶$8.4MraisedJun 2018 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David GuyerDirector
  • James C. TowneDirector
  • Jonathan KilExecutive Officer, Director
  • Joseph AshleyDirector
  • John SullivanExecutive Officer
  • Glenn KawasakiDirector
Offering amount
$10.4M
Amount sold
$8.4M
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.1MraisedSep 2016 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Glenn KawasakiDirector
  • James Paul RickeyExecutive Officer
  • Jonathan KilExecutive Officer, Director
  • Eric LynchExecutive Officer, Director
  • Joseph AshleyDirector
Offering amount
$5M
Amount sold
$4.1M
Minimum investment
$300K
First sale
Aug 2015
Incorporated
Corporation, Washington
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Power33 shared keywordsPower builds a patient-friendly platform to discover and enroll in clinical trials, serving patients seeking access to research studies and researchers seeking to improve patient recruitment. The company operates in the healthcare technology and clinical research industry.
Bioworld24 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Sound Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2003$160K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Seattle's Sound Pharmaceuticals raising $30M to advance trials of hearing-loss drug – GeekWiregeekwire.com · Sep 2016Sound Pharmaceuticals, Inc. Receives Additional DoD Funding for Its Hearing Regeneration Product - BioSpacebiospace.com · Jul 2008

Frequently asked questions

What does Sound Pharmaceuticals do?
Sound Pharmaceuticals (SPI) is a Seattle-based biotech developing drug therapeutics, including its lead candidate SPI-1005, to prevent and treat sensorineural hearing loss, tinnitus, and Meniere's disease. Its treatments target inner ear disorders for which there are currently no FDA-approved drugs.
Who founded Sound Pharmaceuticals?
Sound Pharmaceuticals was founded by Jonathan Kil.
How much funding has Sound Pharmaceuticals raised?
Sound Pharmaceuticals has disclosed $12.5M raised across 2 rounds.
Where is Sound Pharmaceuticals headquartered?
Sound Pharmaceuticals is headquartered in Seattle, US.